Bausch Health Companies Inc is seeing a notable rise in its stock price, thanks to strategic developments in its product offerings.
On the TSX, Bausch Health Companies Inc (BHC.TO) saw its stock increase by 2.39% in the last trading session, closing at CA$6.85. This uptick follows significant news about its subsidiary's product listing in Quebec, which could improve its market position and revenue potential.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.57B
52W high
$11.97
52W low
$6.45
1W change
-4.29%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 4.8% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+4.8% Upside
Current Price
C$6.69
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
50.6%
Annualized
90-Day Vol
42.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.60
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$6.30 | C$5.29 โ C$7.51 |
| 60 trading days | C$5.94 | C$4.64 โ C$7.60 |
| 90 trading days | C$5.60 | C$4.14 โ C$7.57 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Bausch Health's recent developments, as they may indicate a positive trajectory for the company, especially in the Canadian healthcare market.
Bausch Health's stock rises 2.39% in one day
With a market cap of CA$2.57 billion, Bausch Health is strategically positioning itself within the healthcare sector, but profitability remains a concern.
Bull case
The recent listing of PrOKEDI dosages in the RAMQ formulary is a crucial step for Bausch Health. This development could increase patient access and revenue streams, potentially leading to further stock appreciation as the company takes advantage of its market opportunities.
Bear case
Despite the positive news, Bausch Health still faces challenges, including a negative profit margin and ongoing negotiations with other provincial jurisdictions, which could affect future performance.
Key Developments Driving Growth
Bausch Health's announcement about the listing of PrOKEDI dosages in the RAMQ formulary is a pivotal moment for the company. This injectable treatment for schizophrenia is now more accessible, which could lead to increased sales and market share in Quebec. The company's efforts to negotiate similar agreements in other provinces could further boost its revenue.
Market Reaction and Future Outlook
The market's positive response to Bausch Health's news shows investor confidence in the company's strategic direction. As it continues to expand its product offerings and improve access to essential medications, investors may see further growth potential. However, it's important to keep an eye on the company's ongoing financial challenges.
Advertisement
